| Financial Instruments |
Note
12 - Financial Instruments
Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants. The fair value hierarchy ranks the inputs used in measuring fair value as follows:
| |
○ |
Level 1 – Observable, unadjusted
quoted prices in active markets |
| |
○ |
Level 2 – Inputs other than quoted prices included
in Level 1 that are directly or indirectly observable for the asset or liability |
| |
○ |
Level 3 – Unobservable inputs with little or
no market activity that require the Company to use reasonable inputs and assumptions |
The
Company uses fair value measurements to record adjustments to certain financial assets and liabilities on a recurring basis.
The Company may be required to record certain assets at fair value on a nonrecurring basis in specific circumstances,
such as evidence of impairment. Methodologies used to determine fair value might be highly subjective and judgmental in
nature; therefore, valuations may not be precise. If the Company determines that a valuation technique change
is necessary, the change is assumed to have occurred at the end of the respective reporting period.
The following
tables summarize financial assets and liabilities recorded at fair value on a recurring basis, by the level of valuation
inputs in the fair value hierarchy as of March 31, 2026 and December 31, 2025:
Schedule
of Financial Assets and Liabilities Recorded at Fair Value
| | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| | |
As of March 31, 2026 | | |
As of December 31, 2025 | |
| | |
Total Fair Value | | |
Quoted
Prices in Active Markets (Level 1) | | |
Significant
Other Unobservable Inputs (Level 3) | | |
Total Fair Value | | |
Quoted
Prices in Active Markets (Level 1) | | |
Significant
Other Unobservable Inputs (Level 3) | |
| Description | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| Liabilities: | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| PIPE warrants | |
$ | 49 | | |
$ | - | | |
$ | 49 | | |
$ | 280 | | |
$ | - | | |
$ | 280 | |
| Public warrants | |
| 9,459 | | |
| 9,459 | | |
| - | | |
| 10,896 | | |
| 10,896 | | |
| - | |
| Private placement warrants | |
| 2 | | |
| - | | |
| 2 | | |
| 14 | | |
| - | | |
| 14 | |
| Abaca warrant | |
| 13,511 | | |
| - | | |
| 13,511 | | |
| 28,430 | | |
| - | | |
| 28,430 | |
Assets
measured at fair value on a nonrecurring basis
Assets
that are measured at fair value on a nonrecurring basis primarily comprises of property, plant and equipment, right-to-use assets, finite
lived intangible assets and goodwill. The Company does not record these at fair value on a recurring basis, however, the carrying value
of the assets may be reduced to fair value when the Company determines that impairment has occurred.
As
of March 31, 2026, the Company had no assets or liabilities measured at fair value on a non-recurring basis. During the year ended
December 31, 2025, the Company recognized the ASC 460 stand-ready guarantee liability under the Second Amended CAA at fair value on
a non-recurring basis upon initial recognition on October 1, 2025. This liability was measured at inception only and is not
remeasured at fair value in subsequent reporting periods. The carrying amount as of December 31, 2025 was $2.1
million, reflecting the systematic release of the liability as the Company is progressively released from risk on the underlying
loan portfolio. The fair value measurement for stand-ready guarantee liability was prepared internally by management using an
insurance-pricing methodology, reflecting the premium that a knowledgeable, willing third-party surety or specialty insurer would
charge to assume the indemnification obligation in an arm’s-length transaction, consistent with the market participant
framework of ASC 820-10-35-9.
The
following table summarizes this non-recurring fair value measurement as of the initial recognition date:
Schedule of Non-Recurring Fair Value Measurement
| |
| | |
| | |
| | |
| | |
| |
| | |
December 31, 2025 | |
| | |
Carrying amount $ | | |
Fair value $ | | |
Fair value measurement using | |
| | |
| | |
| | |
Level 1 $ | | |
Level 2 $ | | |
Level 3 $ | |
| Liabilities | |
| | |
| | |
| | |
| | |
| |
| Stand-ready guarantee liability | |
$ | 2,135,000 | | |
$ | 2,135,000 | | |
$ | - | | |
$ | - | | |
$ | 2,135,000 | |
Level
3 Measurement - Significant Unobservable Inputs
The
ASC 460 Guarantee liability was classified as Level 3 because its fair value was determined using significant unobservable inputs for
which there is no active market. The following table summarizes the valuation methodology and significant unobservable inputs used in
the Level 3 measurement:
Schedule of Valuation Methodology and Significant Unobservable Inputs
| Input |
|
Value
Used |
|
Sensitivity |
| Probability
of Default -Tranches A & B (Ratings 2–5, pooled) |
|
7.25%,
derived from loan level analysis of the portfolio. |
|
An
increase raises fair value |
| Probability
of Default - Tranche C (Rating 9, individually evaluated) |
|
35%,
based on Rating 9 definition, past-maturity status, and personal guarantees |
|
An
increase raises fair value |
| Loss
Given Default - Tranches A & B |
|
25.00%
for Tranche A and 35% for Tranche B, inclusive of 13% cannabis-specific qualitative premium reflecting court access limitations,
collateral possession restrictions, and refinancing risk |
|
An
increase raises fair value |
| Loss
Given Default - Tranche C (uncollateralized gap) |
|
50%,
representing the midpoint of the Rating 9 anticipated loss range applied to the uncollateralized exposure |
|
An
increase raises fair value |
| Stand-Ready
Risk Premium |
|
120%
loading applied to total expected loss, reflecting compensation for uncapped exposure, cannabis concentration risk, portfolio illiquidity,
and six-year guarantee term commitment |
|
An
increase raises fair value |
| Discount
Rate |
|
4.0%
risk-free rate (6-year Treasury) |
|
An
increase reduces fair value |
| Weighted
Average Payout Timing |
|
Tranche
A: 4 years; Tranche B: 3 years; Tranche C: 2 years; Stand-ready premium: 3 years — based on the portfolio’s contractual
maturity profile |
|
A
longer weighted average payout timing reduces fair value |
Fair Value
of Financial Instruments
The following
tables present the carrying amounts and fair values of financial instruments on a non-recurring basis, by the level of valuation
inputs in the fair value hierarchy, as of March 31, 2026 and December 31, 2025:
Schedule
of Carrying Amount and Fair Value of Financial Instruments
| | |
| | |
| | |
Level 1 $ | | |
Level 2 $ | | |
Level 3 $ | |
| | |
As of March 31, 2026 | |
| | |
Carrying amount $ | | |
Fair value $ | | |
Fair value
measurement using | |
| | |
| | |
| | |
Level 1 $ | | |
Level 2 $ | | |
Level 3 $ | |
| Assets | |
| | | |
| | | |
| | | |
| | | |
| | |
| Cash and cash equivalents | |
$ | 5,897,470 | | |
$ | 5,897,470 | | |
$ | 5,897,470 | | |
$ | - | | |
$ | - | |
| Investment in preferred securities | |
| 1,424,983 | | |
| 1,424,983 | | |
| - | | |
| - | | |
| 1,424,983 | |
| Liabilities | |
| | | |
| | | |
| | | |
| | | |
| | |
| Deferred consideration | |
| 3,000,000 | | |
| 3,000,000 | | |
| 3,000,000 | | |
| - | | |
| - | |
| Public warrants | |
| 9,459 | | |
| 9,459 | | |
| 9,459 | | |
| - | | |
| - | |
| Private placement warrants | |
| 2 | | |
| 2 | | |
| - | | |
| - | | |
| 2 | |
| PIPE warrants | |
| 49 | | |
| 49 | | |
| - | | |
| - | | |
| 49 | |
| Abaca warrants | |
| 13,511 | | |
| 13,511 | | |
| - | | |
| - | | |
| 13,511 | |
| | |
| | |
| | |
Level 1 $ | | |
Level 2 $ | | |
Level 3 $ | |
| | |
As of December 31, 2025 | |
| | |
Carrying amount $ | | |
Fair value $ | | |
Fair value
measurement using | |
| | |
| | |
| | |
Level 1 $ | | |
Level 2 $ | | |
Level 3 $ | |
| Assets | |
| | | |
| | | |
| | | |
| | | |
| | |
| Cash and cash equivalents | |
$ | 6,779,040 | | |
$ | 6,779,040 | | |
$ | 6,779,040 | | |
$ | - | | |
$ | - | |
| Investment in preferred securities | |
| 1,450,000 | | |
| 1,450,000 | | |
| - | | |
| - | | |
| 1,450,000 | |
| Liabilities | |
| | | |
| | | |
| | | |
| | | |
| | |
| Deferred consideration | |
| 3,000,000 | | |
| 3,000,000 | | |
| 3,000,000 | | |
| - | | |
| - | |
| Public warrants | |
| 10,896 | | |
| 10,896 | | |
| 10,896 | | |
| - | | |
| - | |
| Private placement warrants | |
| 14 | | |
| 14 | | |
| - | | |
| - | | |
| 14 | |
| PIPE warrants | |
| 280 | | |
| 280 | | |
| - | | |
| - | | |
| 280 | |
| Abaca warrants | |
| 28,430 | | |
| 28,430 | | |
| - | | |
| - | | |
| 28,430 | |
The
change in the liability measured at fair value on a recurring basis for which the Company has utilized Level 3 inputs
to determine fair value are presented in the following table
Schedule
of Fair Value Assets Measured on Recurring Basis
| | |
PIPE Warrants | | |
Abaca Warrant | | |
Private Placement Warrants | |
| | |
For The Three Months Ended March 31, 2026 | |
| | |
PIPE Warrants | | |
Abaca Warrant | | |
Private Placement Warrants | |
| Balance, January 1, 2026 | |
$ | 280 | | |
$ | 28,430 | | |
$ | 14 | |
| Fair value adjustment | |
| (231 | ) | |
| (14,919 | ) | |
| (12 | ) |
| Balance, March 31, 2026 | |
$ | 49 | | |
$ | 13,511 | | |
$ | 2 | |
| | |
PIPE Warrants | | |
Abaca
Warrant | | |
Private
Placement Warrants | | |
Third
anniversary payment consideration | | |
Forward
Purchase Derivative | |
| | |
For The Three Months Ended March 31, 2025 | |
| | |
PIPE Warrants | | |
Abaca
Warrant | | |
Private
Placement Warrants | | |
Third
anniversary payment consideration | | |
Forward
Purchase Derivative | |
| Balance, January 1, 2025 | |
$ | 79,512 | | |
$ | 1,024,900 | | |
$ | 9,632 | | |
$ | 322,000 | | |
$ | 7,309,580 | |
| Fair value adjustment | |
| (71,918 | ) | |
| (795,652 | ) | |
| (9,110 | ) | |
| (161,000 | ) | |
| - | |
| Balance, March 31, 2025 | |
$ | 7,594 | | |
$ | 229,248 | | |
$ | 522 | | |
$ | 161,000 | | |
$ | 7,309,580 | |
As
of March 31, 2026 and December 31, 2025, the fair market value of the private placement warrants, Abaca warrants and
PIPE warrants, were based on Black-Scholes Merton option pricing model.
As of March 31, 2026 and December 31, 2025, there were no changes in the classification of financial
instruments within Level 2 and Level 3 of the fair value hierarchy.
The following
table provides quantitative information regarding Level 3 fair value measurements inputs as it relates to the private
placement warrants, PIPE warrants, and Abaca warrants as of their measurement
dates:
Schedule
of Level 3 Fair Value Measurements Inputs
| | |
PIPE Warrants | | |
Private Warrants | | |
Abaca Warrants | | |
PIPE Warrants | | |
Private Warrants | | |
Abaca Warrants | |
| | |
As of March 31, 2026 | | |
As of December 31, 2025 | |
| | |
PIPE Warrants | | |
Private Warrants | | |
Abaca Warrants | | |
PIPE Warrants | | |
Private Warrants | | |
Abaca Warrants | |
| Exercise price | |
$ | 100 | | |
$ | 230 | | |
$ | 40 | | |
$ | 100 | | |
$ | 230.00 | | |
$ | 40.00 | |
| Share price | |
$ | 0.83 | | |
$ | 0.83 | | |
$ | 0.83 | | |
$ | 1.06 | | |
$ | 1.06 | | |
$ | 1.06 | |
| Expected term (years) | |
| 1.49 | | |
| 1.49 | | |
| 2.57 | | |
| 1.7 | | |
| 1.7 | | |
| 2.8 | |
| Volatility | |
| 115 | % | |
| 115 | % | |
| 115 | % | |
| 115 | % | |
| 115 | % | |
| 115 | % |
| Risk-free rate | |
| 3.7 | % | |
| 3.7 | % | |
| 3.7 | % | |
| 3.5 | % | |
| 3.5 | % | |
| 3.5 | % |
|
Note
17 - Financial Instruments
Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants. The fair value hierarchy ranks the inputs used in measuring fair value as follows:
| |
○ |
Level
1 – Observable, unadjusted quoted prices in active markets |
| |
○ |
Level
2 – Inputs other than quoted prices included in Level 1 that are directly or indirectly observable for the asset or liability |
| |
○ |
Level
3 – Unobservable inputs with little or no market activity that require the Company to use reasonable inputs and assumptions |
The
Company uses fair value measurements to record adjustments to certain financial assets and liabilities on a recurring basis. The Company
may be required to record certain assets at fair value on a nonrecurring basis in specific circumstances, such as evidence of impairment.
Methodologies used to determine fair value might be highly subjective and judgmental in nature; therefore, valuations may not be precise.
If the Company determines that a valuation technique change is necessary, the change is assumed to have occurred at the end of the respective
reporting period.
Assets
and Liabilities Reported at Fair Value on a Recurring Basis
Public
Warrants:
Public
warrants are recorded at fair value on a recurring basis. The Company obtains exchange traded price, of Level 1 inputs, based on observable
data to value these warrants.
Private
Placement Warrants:
Private
Placement Warrants are recorded at fair value on a recurring basis based upon an internal Company assessed value of these derivatives
with Level 3 inputs, which are derived from the Black-Scholes model.
PIPE
Warrants:
PIPE
Warrants are recorded at fair value on a recurring basis based upon an internal Company assessed value of these derivatives with Level
3 inputs, which are derived from the Black-Scholes model.
Abaca
Warrants:
Abaca
Warrants are recorded at fair value on a recurring basis. The Company assessed the value of these derivatives with Level 3 inputs. Level
3 inputs, based on unobservable data derived from the Black-Scholes model.
Third
anniversary payment consideration:
The
third anniversary payment consideration was classified as a derivative liability under ASC 815, Derivatives and Hedging, and was recorded
at fair value on a recurring basis using Level 3 inputs. On October 3, 2025, the third anniversary payment of $1.5 million, which was
due in October 2025, was settled in full through the issuance of 37,517 shares of Common Stock at a floor value of $40.00 per share at
the Company’s election. As a result of this settlement, the liability was fully extinguished during the year ended December 31,
2025.
Forward
purchase option derivatives:
Forward
purchase option derivatives are recorded at fair value on a recurring basis. On September 30, 2025, all three FPA holders entered into
Exchange and Cancellation Agreements with the Company, pursuant to which they irrevocably cancelled, waived, and terminated all of their
rights under the FPA in exchange for shares of Series B Convertible Preferred Stock and Series B Warrants to purchase Class A Common
Stock. This transaction extinguished the FPA derivative liability in its entirety and was accounted for as a debt extinguishment under
ASC 405-20, resulting in a gain on extinguishment of $3.3 million recognized in Other Income (Expense) for the year ended December 31,
2025.
The
following tables summarize financial assets and liabilities recorded at fair value on a recurring basis, by the level of valuation inputs
in the fair value hierarchy on December 31, 2025 and December 31, 2024:
Schedule of Financial Assets and Liabilities Recorded at Fair Value
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| | |
December 31, 2025 | | |
December 31, 2024 | |
| | |
Total Fair Value | | |
Quoted Prices in Active Markets (Level 1) | | |
Significant Other Unobservable Inputs (Level 3) | | |
Total Fair Value | | |
Quoted Prices in Active Markets (Level 1) | | |
Significant Other Unobservable Inputs (Level 3) | |
| Description | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| Liabilities: | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| PIPE warrants | |
$ | 280 | | |
$ | - | | |
$ | 280 | | |
$ | 79,512 | | |
$ | - | | |
$ | 79,512 | |
| Public warrants | |
| 10,896 | | |
| 10,896 | | |
| - | | |
| 246,445 | | |
| 246,445 | | |
| - | |
| Private placement warrants | |
| 14 | | |
| - | | |
| 14 | | |
| 9,632 | | |
| - | | |
| 9,632 | |
| Abaca warrant | |
| 28,430 | | |
| - | | |
| 28,430 | | |
| 1,024,900 | | |
| - | | |
| 1,024,900 | |
| Forward purchase derivative liability | |
| - | | |
| - | | |
| - | | |
| 7,309,580 | | |
| - | | |
| 7,309,580 | |
| Third anniversary payment consideration | |
| - | | |
| - | | |
| - | | |
| 322,000 | | |
| - | | |
| 322,000 | |
Assets
Measured at Fair Value on a Nonrecurring Basis
Assets
that are measured at fair value on a nonrecurring basis primarily comprises of property, plant and equipment, right-to-use assets, finite
lived intangible assets and goodwill. The Company does not record these at fair value on a recurring basis, however, the carrying value
of the assets may be reduced to fair value when the Company determines that impairment has occurred.
As
of December 31, 2024, the Company had no assets or liabilities measured at fair value on a non-recurring basis. During the year
ended December 31, 2025, the Company recognized the ASC 460 stand-ready guarantee liability under the Second Amended CAA at fair
value on a non-recurring basis upon initial recognition on October 1, 2025. This liability was measured at inception only and is not
remeasured at fair value in subsequent reporting periods. The carrying amount as of December 31, 2025 was $2.1 million, reflecting
the systematic release of the liability as the Company is progressively released from risk on the underlying loan portfolio. The
fair value measurement for stand-ready guarantee liability was prepared internally by management using an insurance-pricing
methodology, reflecting the premium that a knowledgeable, willing third-party surety or specialty insurer would charge to assume the
indemnification obligation in an arm’s-length transaction, consistent with the market participant framework of ASC
820-10-35-9.
The following table summarizes this non-recurring fair value measurement as of the initial recognition date:
Schedule of Non-Recurring Fair Value Measurement
| |
| | |
| | |
| | |
| | |
| |
| | |
December 31, 2025 | |
| | |
Carrying amount $ | | |
Fair value $ | | |
Fair value measurement using | |
| | |
| | |
| | |
Level 1 $ | | |
Level 2 $ | | |
Level 3 $ | |
| Liabilities | |
| | |
| | |
| | |
| | |
| |
| Stand-ready guarantee liability | |
$ | 2,135,000 | | |
$ | 2,135,000 | | |
$ | - | | |
$ | - | | |
$ | 2,135,000 | |
Level
3 Measurement - Significant Unobservable Inputs
The
ASC 460 Guarantee liability was classified as Level 3 because its fair value was determined using significant unobservable inputs for
which there is no active market. The following table summarizes the valuation methodology and significant unobservable inputs used in
the Level 3 measurement:
Schedule of Valuation Methodology and Significant Unobservable Inputs
| Input |
|
Value
Used |
|
Sensitivity |
| Probability of Default -Tranches A & B (Ratings
2–5, pooled) |
|
7.25%, derived from loan level analysis of the portfolio. |
|
An increase raises fair value |
| Probability of Default - Tranche C (Rating 9, individually
evaluated) |
|
35%, based on Rating 9 definition, past-maturity status,
and personal guarantees |
|
An increase raises fair value |
| Loss Given Default - Tranches A & B |
|
25.00% for Tranche A and 35% for Tranche B, inclusive
of 13% cannabis-specific qualitative premium reflecting court access limitations, collateral possession restrictions, and
refinancing risk |
|
An increase raises fair value |
| Loss Given Default - Tranche C (uncollateralized gap) |
|
50%, representing the midpoint of the Rating 9 anticipated
loss range applied to the uncollateralized exposure |
|
An increase raises fair value |
| Stand-Ready Risk Premium |
|
120%
loading applied to total expected loss, reflecting compensation for uncapped exposure, cannabis concentration risk, portfolio
illiquidity, and six-year guarantee term commitment |
|
An increase raises fair value |
| Discount Rate |
|
4.0%
risk-free rate (6-year Treasury) |
|
An increase reduces fair value |
| Weighted Average Payout Timing |
|
Tranche A: 4 years; Tranche B: 3 years; Tranche C:
2 years; Stand-ready premium: 3 years — based on the portfolio’s contractual maturity profile |
|
A longer weighted average payout timing reduces fair
value |
Fair
Value of Financial Instruments
The
following tables present the carrying amounts and fair values of financial instruments on a non-recurring basis, by the level of valuation
inputs in the fair value hierarchy, as of December 31, 2025 and December 31, 2024:
Schedule
of Carrying Amounts and Fair Values of Financial Instruments
| | |
| | |
| | |
Level
1
$ | | |
Level
2
$ | | |
Level
3
$ | |
| | |
December
31, 2025 | |
| | |
Carrying
amount
$ | | |
Fair
value
$ | | |
Fair
value measurement using | |
| | |
| | |
| | |
Level
1
$ | | |
Level
2
$ | | |
Level
3
$ | |
| Assets | |
| | |
| | |
| | |
| | |
| |
| Cash and cash
equivalents | |
$ | 6,779,040 | | |
$ | 6,779,040 | | |
$ | 6,779,040 | | |
$ | - | | |
$ | - | |
| Forward purchase agreement | |
| | | |
| | | |
| | | |
| | | |
| | |
| Loans | |
| | | |
| | | |
| | | |
| | | |
| | |
| Investment in preferred
securities | |
| 1,450,000 | | |
| 1,450,000 | | |
| - | | |
| - | | |
| 1,450,000 | |
| Liabilities | |
| | | |
| | | |
| | | |
| | | |
| | |
| Deferred consideration | |
| 3,000,000 | | |
| 3,000,000 | | |
| 3,000,000 | | |
| - | | |
| - | |
| Public warrants | |
| 10,896 | | |
| 10,896 | | |
| 10,896 | | |
| - | | |
| - | |
| Private placement warrants | |
| 14 | | |
| 14 | | |
| - | | |
| - | | |
| 14 | |
| PIPE warrants | |
| 280 | | |
| 280 | | |
| - | | |
| - | | |
| 280 | |
| Abaca warrants | |
| 28,430 | | |
| 28,430 | | |
| - | | |
| - | | |
| 28,430 | |
| | |
| | |
| | |
Level
1
$ | | |
Level
2
$ | | |
Level
3
$ | |
| | |
December
31, 2024 | |
| | |
Carrying
amount
$ | | |
Fair
value
$ | | |
Fair
value measurement using | |
| | |
| | |
| | |
Level
1
$ | | |
Level
2
$ | | |
Level
3
$ | |
| Assets | |
| | |
| | |
| | |
| | |
| |
| Cash and cash equivalents | |
$ | 2,324,647 | | |
$ | 2,324,647 | | |
$ | 2,324,647 | | |
$ | - | | |
$ | - | |
| Forward purchase agreement | |
| 4,584,221 | | |
| 4,584,221 | | |
| 4,584,221 | | |
| - | | |
| - | |
| Loans | |
| 360,552 | | |
| 359,505 | | |
| - | | |
| - | | |
| 359,505 | |
| Liabilities | |
| | | |
| | | |
| | | |
| | | |
| | |
| Deferred consideration | |
| 3,016,343 | | |
| 3,016,343 | | |
| 3,016,343 | | |
| - | | |
| - | |
| Senior secured promissory note | |
| 11,004,173 | | |
| 10,221,652 | | |
| - | | |
| - | | |
| 10,221,652 | |
| Public warrants | |
| 246,445 | | |
| 246,445 | | |
| 246,445 | | |
| - | | |
| - | |
| Private placement warrants | |
| 9,632 | | |
| 9,632 | | |
| - | | |
| - | | |
| 9,632 | |
| PIPE warrants | |
| 79,512 | | |
| 79,512 | | |
| - | | |
| - | | |
| 79,512 | |
| Abaca warrants | |
| 1,024,900 | | |
| 1,024,900 | | |
| - | | |
| - | | |
| 1,024,900 | |
| Third anniversary payment consideration | |
| 322,000 | | |
| 322,000 | | |
| - | | |
| - | | |
| 322,000 | |
| Forward purchase derivative | |
| 7,309,580 | | |
| 7,309,580 | | |
| - | | |
| - | | |
| 7,309,580 | |
The
change in the liability measured at fair value on a recurring basis for which the Company has utilized Level 3 inputs to determine fair
value are presented in the following table:
Schedule of Fair Value Assets Measured on Recurring Basis
| | |
PIPE
Warrants | | |
Abaca
Warrant | | |
Private
Placement Warrants | | |
Third
anniversary payment consideration | | |
Forward
Purchase Derivative | |
| | |
For
the Year Ended December 31, 2025 | | |
| |
| | |
PIPE
Warrants | | |
Abaca
Warrant | | |
Private
Placement Warrants | | |
Third
anniversary payment consideration | | |
Forward
Purchase Derivative | |
| Balance, January 1, 2025 | |
$ | 79,512 | | |
$ | 1,024,900 | | |
$ | 9,632 | | |
$ | 322,000 | | |
$ | 7,309,580 | |
| Fair value adjustment | |
| (79,232 | ) | |
| (996,470 | ) | |
| (9,618 | ) | |
| (63,133 | ) | |
| - | |
| Exchanged for Common Stock |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
258,867 |
|
|
|
- |
|
| Exchanged for Series B
Convertible Preferred Stock and Series B Warrants | |
| - | | |
| - | | |
| - | | |
| - | | |
| (7,309,580 | ) |
| Balance, December 31, 2025 | |
$ | 280 | | |
$ | 28,430 | | |
$ | 14 | | |
$ | - | | |
$ | - | |
| | |
PIPE
Warrants | | |
Abaca
Warrant | | |
Private
Placement Warrants | | |
Third
anniversary payment consideration | | |
Forward
Purchase Derivative | |
| | |
For
the Year ended December 31, 2024 | | |
| |
| | |
PIPE
Warrants | | |
Abaca
Warrant | | |
Private
Placement Warrants | | |
Third
anniversary payment consideration | | |
Forward
Purchase Derivative | |
| Balance, January 1, 2024 | |
$ | 273,124 | | |
$ | 3,384,085 | | |
$ | 25,070 | | |
$ | 810,000 | | |
$ | 7,309,580 | |
| Beginning balance | |
$ | 273,124 | | |
$ | 3,384,085 | | |
$ | 25,070 | | |
$ | 810,000 | | |
$ | 7,309,580 | |
| Fair value adjustment | |
| (193,612 | ) | |
| (2,359,185 | ) | |
| (15,438 | ) | |
| (488,000 | ) | |
| - | |
| Balance, December 31, 2024 | |
$ | 79,512 | | |
| 1,024,900 | | |
$ | 9,632 | | |
$ | 322,000 | | |
$ | 7,309,580 | |
| Ending balance | |
$ | 79,512 | | |
| 1,024,900 | | |
$ | 9,632 | | |
$ | 322,000 | | |
$ | 7,309,580 | |
As
of December 31, 2025 and on December 31, 2024, the fair market of the private placement warrants, Abaca warrants and PIPE warrants,
were based on Black-Scholes Merton option pricing model. The valuation was performed by the Company
as of December 31, 2025, and by a third-party prior for prior periods.
During
the year ended December 31, 2025 and December 31, 2024, there were no changes in the classification of financial instruments within Level
2 and Level 3 of the fair value hierarchy.
The
following table provides quantitative information regarding Level 3 fair value measurements inputs as it relates to the private placement
warrants, public warrants, third anniversary payment consideration and Abaca warrants as of their measurement dates:
Schedule of Level 3 Fair Value Measurements Inputs
| | |
PIPE
Warrants | | |
Private
Warrants | | |
Third
Anniversary Payment Consideration | | |
Abaca
Warrants | | |
PIPE
Warrants | | |
Private
Warrants | | |
Third
Anniversary Payment Consideration | | |
Abaca
Warrants | |
| | |
As
on December 31, 2025 | | |
| | |
As
on December 31, 2024 | | |
| |
| | |
PIPE
Warrants | | |
Private
Warrants | | |
Third
Anniversary Payment Consideration | | |
Abaca
Warrants | | |
PIPE
Warrants | | |
Private
Warrants | | |
Third
Anniversary Payment Consideration | | |
Abaca
Warrants | |
| Exercise price | |
$ | 100 | | |
$ | 230.00 | | |
$ | - | | |
$ | 40.00 | | |
$ | 100.00 | | |
$ | 230.00 | | |
$ | - | | |
$ | 40.00 | |
| Share price | |
$ | 1.06 | | |
$ | 1.06 | | |
$ | - | | |
$ | 1.06 | | |
$ | 9.00 | | |
$ | 9.00 | | |
$ | 9.00 | | |
$ | 9.00 | |
| Expected term (years) | |
| 1.7 | | |
| 1.7 | | |
| - | | |
| 2.8 | | |
| 2.7 | | |
| 2.7 | | |
| 0.8 | | |
| 3.87 | |
| Volatility | |
| 115 | % | |
| 115 | % | |
| - | | |
| 115 | % | |
| 103 | % | |
| 103 | % | |
| 103 | % | |
| 103 | % |
| Risk-free rate | |
| 3.5 | % | |
| 3.5 | % | |
| - | | |
| 3.5 | % | |
| 4.3 | % | |
| 4.3 | % | |
| 4.3 | % | |
| 4.3 | % |
| Measurement input | |
| 3.5 | % | |
| 3.5 | % | |
| - | | |
| 3.5 | % | |
| 4.3 | % | |
| 4.3 | % | |
| 4.3 | % | |
| 4.3 | % |
On
October 3, 2025, the Company issued 37,517 shares of Common Stock to the Abaca shareholders as part of the third anniversary consideration
payment under the acquisition agreement (see Note 3), valued at $0.3 million.
|